Skip to main content
Caplight Logo









Lassen Therapeutics

Lassen Therapeutics

Private
San Diego, CaliforniaHealthcare & Life Scienceshttps://lassentherapeutics.com/

Last Round

Series B

Dec 19, 2023

Total Funding Raised

$116M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Lassen Therapeutics is a biopharmaceutical company that develops antibody-based therapeutics for the treatment of fibrotic, inflammatory, and oncology-related diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

monoclonal antibodybiotechfibrosis treatmentIL-11 pathwayclinical-stage biotechthyroid eye diseasedrug developmentbiopharmatherapeutic antibodyfibrotic diseaseoncologydrug discoveryclinical trialsrare disease

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Lassen Therapeutics Comparables

Compare Lassen Therapeutics with similar companies based on industry and business-model similarity.

Lassen Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Novartis
79%
Alphabet Inc.
74%
Amgen
74%

Lassen Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BDec 19, 2023
Series AJun 17, 2020

Key People

Founding team and executive leadership

Mark Barrett

Founder, CEO Board Member (2018-23) Advisor (current)

Founding Team

Lassen Therapeutics Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 29, 2026

    Monthly visitors increased 118% MoM.

  • Jun 17, 2020

    $31M round led by Frazier Healthcare Partners

Lassen Therapeutics Filings

Explore SEC and related filing metadata, where available.

Lassen Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Lassen Therapeutics's valuation, stock price, and market status.

Is Lassen Therapeutics a public or private company?

Lassen Therapeutics is a private company.

What is the current stock price of Lassen Therapeutics?

Lassen Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is Lassen Therapeutics worth (valuation)?

Valuation information for Lassen Therapeutics is not publicly available.

Can I buy Lassen Therapeutics stock?

Lassen Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Lassen Therapeutics's last funding round?

Lassen Therapeutics's most recent funding round was Series B on December 19, 2023.

Who are the main investors in Lassen Therapeutics?

Key investors in Lassen Therapeutics include Longitude Capital, Frazier Healthcare Partners, Frazier Life Sciences.

Will Lassen Therapeutics IPO soon?

No public IPO plans have been announced for Lassen Therapeutics.

How can I track Lassen Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Lassen Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSan Diego, California
Employee Range10
Year Founded2018
Last FundingDec 19, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?